Enlivex Therapeutics (ENLV) Institutional Ownership $0.98 -0.05 (-4.87%) (As of 11/20/2024 ET) Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Enlivex Therapeutics (NASDAQ:ENLV)CurrentInstitutional OwnershipPercentage1.02%Number ofInstitutional Buyers(last 12 months)3TotalInstitutional Inflows(last 12 months)$2.50MNumber ofInstitutional Sellers(last 12 months)0 Get ENLV Insider Trade Alerts Want to know when executives and insiders are buying or selling Enlivex Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ENLV Institutional Buying and Selling by Quarter Ad Wyatt Investment ResearchMy #1 Pre IPO Trade for 2025 – NAME and TICKEROne tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...The Next SpaceX Pre-IPO Enlivex Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails10/23/2024 Sigma Investment Counselors Inc.30,000$50K0.0%N/A0.140% 8/15/2024 Armistice Capital LLC1,700,571$2.42M0.0%N/A8.148% 8/12/2024 XTX Topco Ltd24,820$35K0.0%N/A0.119% 5/1/2023 Compagnie Lombard Odier SCmA65,000$225K0.0%+30.0%0.350% 2/9/2023 Group One Trading L.P.13,499$53K0.0%+2,689.0%0.073% 7/11/2022 ARK Investment Management LLC331,001$1.66M0.0%-23.8%1.802% Get the Latest News and Ratings for ENLV and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Enlivex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 4/27/2022 Compagnie Lombard Odier SCmA50,000$279K0.0%+16.3%0.273% 4/20/2022 Belvedere Trading LLC14,473$101K0.0%-13.9%0.079% 4/19/2022 ARK Investment Management LLC434,343$2.43M0.0%+24.3%2.372% 2/9/2022 Compagnie Lombard Odier SCmA43,000$247K0.0%+22.9%0.235% 2/3/2022ACT Capital Management LLC25,000$156K0.1%-69.7%0.137% 1/28/2022 ARK Investment Management LLC349,308$2.18M0.0%-23.7%1.908% 1/21/2022Golden Green Inc.19,967$125K0.1%-54.7%0.109% 11/12/2021 Renaissance Technologies LLC87,989$869K0.0%-55.0%0.481% 10/28/2021 Compagnie Lombard Odier SCmA35,000$353K0.0%+40.0%0.191% 10/8/2021Golden Green Inc.44,085$436K0.3%-4.2%0.241% 8/13/2021 Renaissance Technologies LLC195,706$1.74M0.0%-32.6%1.242% 8/11/2021 Banque Cantonale Vaudoise10,000$89K0.0%N/A0.063% 8/5/2021 ARK Investment Management LLC514,807$4.58M0.0%+8.1%3.267% 7/17/2021Golden Green Inc.46,020$410K0.3%-34.1%0.292% 5/18/2021 Jane Street Group LLC11,070$123K0.0%N/A0.070% 5/17/2021 Edmond DE Rothschild Holding S.A.13,000$144K0.0%N/A0.082% 5/17/2021 Goldman Sachs Group Inc.12,986$144K0.0%N/A0.082% 5/13/2021 ARK Investment Management LLC476,414$5.28M0.0%N/A3.023% 5/13/2021 Renaissance Technologies LLC290,406$3.22M0.0%+4.0%1.843% 5/12/2021 UBS Group AG10,872$120K0.0%-51.5%0.069% 4/23/2021 Compagnie Lombard Odier SCmA25,000$267K0.0%N/A0.159% 4/13/2021Golden Green Inc.69,782$774K0.7%+51.5%0.443% 2/10/2021 Renaissance Technologies LLC279,106$2.35M0.0%-6.5%2.073% 1/25/2021Golden Green Inc.46,056$388K0.4%N/A0.342% 11/17/2020 Jane Street Group LLC10,807$64K0.0%-64.8%0.080% (Data available from 1/1/2016 forward) ENLV Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ENLV shares? During the previous two years, the following institutional investors and hedge funds held shares of Enlivex Therapeutics shares: Armistice Capital LLC ($2.42M), Compagnie Lombard Odier SCmA ($225K), Group One Trading L.P. ($53K), and Sigma Investment Counselors Inc. ($50K), XTX Topco Ltd ($35K).Learn more on ENLV's institutional investors. What percentage of Enlivex Therapeutics stock is owned by institutional investors? 1.02% of Enlivex Therapeutics stock is owned by institutional investors. Learn more on ENLV's institutional investor holdings. Which institutional investors have been buying Enlivex Therapeutics stock? The following institutional investors have purchased Enlivex Therapeutics stock in the last 24 months: Armistice Capital LLC ($1.70M), Sigma Investment Counselors Inc. ($30K), XTX Topco Ltd ($24.82K), Compagnie Lombard Odier SCmA ($15K), and Group One Trading L.P. ($13.02K). How much institutional buying is happening at Enlivex Therapeutics? Institutional investors have bought a total of 1,783,406 shares in the last 24 months. This purchase volume represents approximately $2.61M in transactions. Related Companies GNLX Institutional Ownership ME Institutional Ownership CASI Institutional Ownership FBLG Institutional Ownership PMVP Institutional Ownership ONCY Institutional Ownership IKNA Institutional Ownership CMRX Institutional Ownership PDSB Institutional Ownership CLSD Institutional Ownership This page (NASDAQ:ENLV) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enlivex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ENLV Stock Alerts